The fake drug is packaged to resemble the oral cancer treatment Iclusig, which contains the active ingredient ponatinib to fight chronic leukemia and acute lymphoblastic leukemia.
However, the fake drug does not have the active ingredient, which makes it ineffective.
“There’s no active ingredient, so it’s a really high value product,” Michael Deats, who leads the group that runs surveillance on fake medications at the WHO, told The Guardian. “It’s dangerous. We’re concerned about this one.”
Iclusig is expensive, priced around $13,500, or $450 a pill, in the U.S.
“Just the mere fact it’s circulating [is a concern]. You don’t know how much there is, you don’t know what quantities are in existence, and there are sometimes wholesalers that will act unscrupulously, and that’s how it can get into the system as well. Everyone needs to be on their guard that this is in circulation,” Mr. Deats said.
More articles on pharmacy:
Better pharmacy access sought for rural Colorado residents
Following its rival, Sanofi and Regeneron slash price of cholesterol drug by 60%
Mount Carmel’s chief pharmacy officer out amid overprescribing scandal
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
